Gentherm Inc (THRM) オプション

#BreakingNews Therma Bright $THRM.V $TBRIF Signs SPA for Blood Clot Prevention Technology

Toronto, Ontario--(January 19, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd. ("Inretio") an Isreal Based company for its innovative protective blood clot retriever technology. Read more

https://finance.yahoo.com/news/therma-bright-inc-invests-ischemic-130000496.html

#BreakingNews - Therma Bright 2022 Accomplishments & Update - $THRM.V $TBRIF https://www.newsfilecorp.com/release/148972

This Must Be The Week Of Gentherm: Analysts Predict Big Figures On October 29

https://pennystocks.news/this-must-be-the-week-of-gentherm-analysts-predict-big-figures-on-october-29-thrm/

NOPE----Still too risky----am staying put with lotsa cash and some gold

News: $THRM Gentherm to Participate in the J.P. Morgan Auto Conference

NORTHVILLE, Mich., July 26, 2019 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader and developer of innovative thermal management technologies, today announced that Phil Eyler, President and CEO, and Matteo Anversa, Executive Vice President, CFO and Treasurer, will partic...

Find out more Gentherm to Participate in the J.P. Morgan Auto Conference

Took a position in THRM today. Anyone else in this on the board? Surprised to see it at 52 week lows

Here are my updated buy levels for THRM.

I like the strength of THRM on the weekly for a decent swing trade setup after it has a further sell off. It could just keep going up, but if I was going to take a position in this stock I'd need to see it pullback to the $33-36 range. Watch the RSI as it's very overbought and needs to go under 50 at a minimum before I'd feel comfortable buying a starter position.

Per yahoo finance:

Gentherm Incorporated designs, develops, and manufactures thermal management technologies and cable systems worldwide. It operates through three segments: Climate Controlled Seats (CCS), Advanced Technology, and W.E.T.

50% gain around July if you bought this on margin soon

Skin aesthetic company Thermage to buy Reliant Technologies for $95M
Thermage Inc. will acquire Reliant Technologies Inc. in a stock and cash transaction valued at approximately $95 million, the companies said Monday.

Hayward-based Thermage (NASDAQ: THRM) focuses on non-invasive skin tightening; Mountain View-based Reliant Technologies is a privately held company that focuses on skin resurfacing through its Fraxel line of products.

The companies said the deal would "combine market leaders in skin tightening and skin resurfacing, the two fastest growing segments of the industry."

Thermage and Reliant generated nearly $137 million in revenue on a combined basis for the 12 months ended March 31.

"The transaction is expected to create cross selling opportunities in the domestic and international markets," the companies said, adding that annual cost savings from the combination are expected to be approximately $14 million.

The boards of both companies have approved the proposed transaction, which is subject to customary closing conditions, including approval by the stockholders of Thermage.

The stockholders of Reliant have already approved the transaction by written consent.

"This proposed combination brings together two companies with premier technologies and market positions in their respective fields and creates a company with significantly more potential than either company can realize on its own," said Eric Stang, president and CEO of Reliant Technologies. "Through this combination, Thermage and Reliant Technologies are leading the way toward industry consolidation and establishing a stronger company capable of continued industry leadership."

Reliant Technologies generated approximately $72.5 million in revenue during the 12 months ended March 31.

Photos: Thermage Presents New Guidelines To Enhance Liposuction Results
Wednesday June 25, 8:00 am ET
Thermage is the recommended solution for post liposuction skin tightening

HAYWARD, Calif., June 25 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM - News) announced the introduction of recommended procedure guidelines for physicians when performing Thermage in combination with liposuction. Thermage promotes improved results and helps to minimize common side effects from liposuction when used in combination with liposuction procedures.

To view the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/thermage/33777/

"Uneven surface and skin laxity after liposuction are very common, especially in patients of certain age or if the patient's weight changes," said Dr. Alex De Souza, a Plastic Surgeon with offices in Charleston, West Virginia. "I use Thermage as the best non-invasive treatment available to correct these minor imperfections and obtain smoother results which translates to happier patients."

The American Society of Plastic Surgeons (ASPS)*, the American Society for Aesthetic Plastic Surgery (ASAPS)** and the International Society of Aesthetic Plastic Surgeons (ISAPS) mention asymmetry, rippling of the skin, bumps, uneven surfaces and loose skin as the most common unwanted results of liposuction.

When the Thermage procedure is performed after a liposuction surgery it can help reduce these surgical side effects with proven skin tightening and deep contouring of the body. Thermage can further improve the results of liposuction, increasing patient satisfaction with the overall outcome.

"Several of our clinicians have been using Thermage for post-liposuction skin tightening and body shaping for some time now," said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer at Thermage. "The results they are seeing are remarkable and, in the opinion of these doctors, Thermage offers an excellent solution for the correction of unwanted results of liposuction."

These new guidelines will be presented for the first time during a webinar by Dr. Alex De Souza on June 25th, 2008 at 5:00pm PDT. For details and to register go to http://www.thermage.com/physicians/events.cfm.

Thermage has been safely used on over 500,000 patients worldwide to stimulate existing collagen and promote new collagen growth. Patients benefit from a single treatment and results can be subtle to dramatic depending on the individual patient. All Thermage procedures use a unique, patented monopolar capacitive radiofrequency technology for volumetric heating of the tissue that is backed by years of clinical research and has been featured in over 45 peer-reviewed scientific articles.

Thermage Announces First Quarter 2008 Financial Results
Thursday May 8, 4:01 pm ET
Systems and Tip Revenue Up Domestically and Internationally
U.S. Sales Increase 8% Year-Over-Year
U.S. ThermaCool NXT System Sales Grow 29% Year-Over-Year

HAYWARD, Calif., May 8 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM - News), a leader in non-invasive tissue tightening in the aesthetic industry, reported today its financial results for the first quarter ended March 31, 2008.

Revenue for the first quarter of 2008 was $16.2 million, up 7% from $15.2 million for the first quarter of 2007. Domestic revenue increased 8% and international revenue was up 6% compared with the prior year's first quarter. Gross profit for the first quarter of 2008 was $11.9 million, representing 73.2% of revenue, compared with $11.0 million, or 72.6% of revenue, for the same quarter of 2007.

The Company reported a net loss of $2.2 million, or $(0.09) per share, versus net income of $0.1 million, or breakeven earnings per share, for the same quarter of the prior year. Non-GAAP (1) net loss for the first quarter of 2008 was $1.3 million, or $(0.05) per share, compared to net income of $1.3 million, or $0.05 per diluted share, for the prior year period. Included in the first quarter 2008 net loss were approximately $1.0 million of expenses for business development activities that were terminated during the quarter.

"We grew revenue both in the U.S. and internationally, despite a softening aesthetics market," said Stephen J. Fanning, Chairman, President and Chief Executive Officer. "Revenue from both treatment tips and systems increased during the quarter. Our systems sales during the quarter included a high percentage of upgrades for existing customers, the second highest quarter for upgrade units since the NXT system was introduced in the first quarter of 2007. The growth in upgrades demonstrates the continued commitment by our customers to Thermage procedures."

"Thermage is focused on a strategy that includes organic growth, as well as complementary acquisitions that add value for our customers and shareholders," continued Mr. Fanning. "One of the primary reasons behind our IPO was to raise funds that would allow us to pursue this strategy. During the first quarter, we reached an advanced stage of negotiations with a potential acquisition target and had performed significant due diligence on the project before negotiations were terminated. We incurred approximately $1.0 million in outside advisory fees pursuing this acquisition. We remain committed to our strategy to build our presence in the aesthetics market, both organically and through acquisitions that will allow us to expand our product offerings to our customer base and leverage our operating infrastructure."

"Looking at the remainder of 2008, the recent bifurcation of our domestic salesforce, innovative sales strategies such as our Infinity program, and recently introduced tips and procedures, we believe we are positioned for continued revenue growth. While we anticipate that economic conditions will remain challenging throughout the year, we will continue our focus to drive revenue, expand market share, and build upon our reputation as a leader in safe, effective skin tightening and contouring procedures," concluded Mr. Fanning.

Guidance:

Management currently expects 2008 revenue to be in a range of $67 million to $70 million. With the revised revenue guidance, as well as the business development expenses incurred during the first quarter, the Company expects net income for the full year 2008 on a GAAP basis to be between breakeven and $0.03 per diluted share. Non-GAAP (1) net income for the full year 2008, which excludes estimated stock based compensation charges of approximately $4.6 million, is expected to be in a range of $0.18 to $0.21 per diluted share. The per share earnings amounts are based on weighted average shares of 26 million.

Non-GAAP Presentation:
(1) To supplement the condensed financial information presented on a GAAP
basis, management has provided non-GAAP net income and loss, and
non-GAAP earnings per share measures that exclude the impact of all
stock-based compensation expenses, net of income taxes. The Company
believes that these non-GAAP financial measures provide investors with
insight into what is used by management to conduct a more meaningful
and consistent comparison of the Company's ongoing operating results
and trends, compared with historical results. This presentation is
also consistent with management's internal use of the measure, which
it uses to measure the performance of ongoing operating results,
against prior periods and against our internally developed targets. A
table reconciling the GAAP financial measures to the non-GAAP measures
is included in the condensed financial information attached to this
release.

Conference Call

The conference call is scheduled to begin at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2008. The call will be broadcast live over the Internet hosted at the Investor Relations section of the Company's website at http://www.thermage.com. In addition, you may call to listen to the live broadcast: 866-249-5225 for domestic participants and 303-262-2006 for international participants. Participating in the call will be Stephen J. Fanning, Chairman, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain accessible for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers. Both callers will need to use the Passcode 11113200#. An archived webcast will also be available at http://www.thermage.com.

Thermage Announces Technological Advances Featured at ASLMS Meeting
Thursday April 3, 8:00 am ET

KISSIMMEE, Fla., April 3, 2008 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM - News) today announced that physician investigators will be presenting clinical research using Thermage technology during the 28th Annual Conference for the American Society for Laser Medicine & Surgery (ASLMS), from both the podium and during a Thermage organized symposium featuring leading experts in the field.

Topics covered during the meeting include advances in skin tightening technology, clinical outcomes using the deep contouring tip for Body Shape procedures and the new treatment for cellulite. Additionally research will be presented on how Thermage technology may be applied for future applications such as fat reduction.

Thermage technology will be featured in the following sessions:

-- Anne C. Chapas, M.D., Skin Rejuvenation Session April 3rd
8 a.m. - 12 p.m.

-- Robert A. Weiss, M.D. Skin Rejuvenation Session April 3rd
8 a.m. - 12 p.m.

-- Christopher Zachary, M.D. "Effects of Monopolar Radiofrequency on the
subcutaneous fat layer in an animal model", Cutaneous Laser Surgery
Session April 6th 8.55 a.m.


Clinical studies accepted as poster presentations include:

-- Sofia Rubbani, M.D. "Advances in Monopolar Radiofrequency for the
treatment of stretch marks in the arms, thighs and abdomens"

-- Neil Saddick, M.D "Immediate effect of a new monopolar radiofrequency
treatment tip on cellulite"


The Thermage Symposium will be held on Thursday April 3rd at 7pm at the Gaylord Palms Resort, Osceola B. The symposium will be moderated by Jeffrey Dover, M.D and will feature Robert Weiss, M.D, Karyn Grossman, M.D and Suzanne Bruce, M.D. The symposium will cover how continual innovation has maintained Thermage technology as the gold standard in skin tightening and contouring for face and body. There will also be a discussion on how Thermage technology and these new applications can be integrated into an aesthetic practice.

"Thermage is dedicated to continual innovation to expand our platform with new applications and to drive the efficacy and value of our products to meet the needs of our customers," said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer at Thermage. "The clinical findings being presented at ASLMS are a testament to our commitment to commercialize products that are based on thorough scientific and clinical research as well as our long-standing partnerships with pre-eminent researchers and practitioners in the field."

FORM S-8 going lower

REGISTRATION STATEMENT

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D08%2D057601%2Etxt&FilePath=%5C2008%5C03%5C14%5C&CoName=THERMAGE+INC&FormType=S%2D8&RcvdDate=3%2F14%2F2008&pdf=

Thermage Q4 2007 Earnings Call Transcript:

http://seekingalpha.com/article/65983-thermage-q4-2007-earnings-call-transcript?source=yahoo